These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 31570827)

  • 1. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
    Morel D; Jeffery D; Aspeslagh S; Almouzni G; Postel-Vinay S
    Nat Rev Clin Oncol; 2020 Feb; 17(2):91-107. PubMed ID: 31570827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of epigenetic therapy in solid tumours--lessons from the past.
    Azad N; Zahnow CA; Rudin CM; Baylin SB
    Nat Rev Clin Oncol; 2013 May; 10(5):256-66. PubMed ID: 23546521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Therapies and Potential Drugs for Treating Human Cancer.
    Lin SQ; Li X
    Curr Drug Targets; 2020; 21(11):1068-1083. PubMed ID: 32209040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
    Singh D; Khan MA; Siddique HR
    Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a more precise therapy in cancer: Exploring epigenetic complexity.
    Cossío FP; Esteller M; Berdasco M
    Curr Opin Chem Biol; 2020 Aug; 57():41-49. PubMed ID: 32480315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical advances in targeting epigenetics for cancer therapy.
    Feng S; De Carvalho DD
    FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
    Buocikova V; Rios-Mondragon I; Pilalis E; Chatziioannou A; Miklikova S; Mego M; Pajuste K; Rucins M; Yamani NE; Longhin EM; Sobolev A; Freixanet M; Puntes V; Plotniece A; Dusinska M; Cimpan MR; Gabelova A; Smolkova B
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidrugs: targeting epigenetic marks in cancer treatment.
    Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
    Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
    Xu Y; Li P; Liu Y; Xin D; Lei W; Liang A; Han W; Qian W
    Cancer Commun (Lond); 2022 Jun; 42(6):493-516. PubMed ID: 35642676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic perspectives on cancer chemotherapy response.
    Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
    Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET Proteins as Attractive Targets for Cancer Therapeutics.
    Sarnik J; Popławski T; Tokarz P
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors.
    Liu Z; Gao Y; Li X
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):139-149. PubMed ID: 30470148
    [No Abstract]   [Full Text] [Related]  

  • 19. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
    Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
    Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer epigenetics: Moving forward.
    Nebbioso A; Tambaro FP; Dell'Aversana C; Altucci L
    PLoS Genet; 2018 Jun; 14(6):e1007362. PubMed ID: 29879107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.